西藏药业：10月30日召开董事会会议

Group 1 - The core viewpoint of the article is that Tibet Pharmaceutical (SH 600211) held its 11th meeting of the 8th Board of Directors on October 30, 2025, via telecommunication, where it reviewed the Q3 2025 report and other documents [1] - For the first half of 2025, Tibet Pharmaceutical's revenue composition was as follows: pharmaceutical commerce accounted for 97.37%, pharmaceutical manufacturing accounted for 68.9%, and other businesses accounted for 0.2%, with inter-segment eliminations at -66.47% [1]